PANDx – Advancing Infectious Disease Diagnostics with NGS Solutions
PANDx is a Singapore-based biotech company specializing in the R&D and production of IVD reagents and molecular diagnostic solutions, with a strong focus on infectious disease detection through Next Generation Sequencing (NGS). The company provides integrated solutions for standardized pathogenic molecular detection, supporting healthcare institutions in establishing end-to-end NGS-based diagnostic platforms. These platforms combine reagents, instruments, software, and application support into a closed-loop system to enhance precision diagnostics and pathogen surveillance.
PANDx is positioned to become a key player in metagenomic (mNGS) and targeted NGS (tNGS) across Asia. In 2024 alone, PANDx processed over 500,000 clinical samples, with projected annual growth of 60%. The company collaborates closely with clinical laboratories and academic partners, contributing to the field through the publication of more than 30 SCI-indexed articles in microbiology and infectious diseases over the past three years.
Through continuous innovation and a comprehensive NGS service model, PANDx empowers hospitals and laboratories to effectively detect emerging pathogens and improve patient outcomes with advanced molecular diagnostics